Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

AP Kater; JF Seymour; P Hillmen; B Eichhorst; Ton Langerak; C Owen; M Verdugo; J Wu; EA Punnoose; YW Jiang; Johnny Wang; M Boyer; K Humphrey; M Mobasher; TJ Kipps

doi:10.1200/jco.18.01580

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

AP Kater, JF Seymour, P Hillmen, B Eichhorst, Ton Langerak, C Owen, M Verdugo, J Wu, EA Punnoose, YW Jiang, Johnny Wang, M Boyer, K Humphrey, M Mobasher, TJ Kipps

Immunology

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

271 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	269-+
Journal	Journal of Clinical Oncology
Volume	37
Issue number	4
DOIs	https://doi.org/10.1200/jco.18.01580
Publication status	Published - 2019

Research programs

EMC MM-02-72-01

Access to Document

10.1200/jco.18.01580

http://hdl.handle.net/1765/115195

Cite this

Kater, AP., Seymour, JF., Hillmen, P., Eichhorst, B., Langerak, T., Owen, C., Verdugo, M., Wu, J., Punnoose, EA., Jiang, YW., Wang, J., Boyer, M., Humphrey, K., Mobasher, M., & Kipps, TJ. (2019). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 37(4), 269-+. https://doi.org/10.1200/jco.18.01580

@article{283d711f956a4e118fe9f2022c7fb984,

title = "Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study",

author = "AP Kater and JF Seymour and P Hillmen and B Eichhorst and Ton Langerak and C Owen and M Verdugo and J Wu and EA Punnoose and YW Jiang and Johnny Wang and M Boyer and K Humphrey and M Mobasher and TJ Kipps",

year = "2019",

doi = "10.1200/jco.18.01580",

language = "Undefined/Unknown",

volume = "37",

pages = "269--+",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "4",

}

Kater, AP, Seymour, JF, Hillmen, P, Eichhorst, B, Langerak, T, Owen, C, Verdugo, M, Wu, J, Punnoose, EA, Jiang, YW, Wang, J, Boyer, M, Humphrey, K, Mobasher, M & Kipps, TJ 2019, 'Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study', Journal of Clinical Oncology, vol. 37, no. 4, pp. 269-+. https://doi.org/10.1200/jco.18.01580

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. / Kater, AP; Seymour, JF; Hillmen, P et al.
In: Journal of Clinical Oncology, Vol. 37, No. 4, 2019, p. 269-+.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

AU - Kater, AP

AU - Seymour, JF

AU - Hillmen, P

AU - Eichhorst, B

AU - Langerak, Ton

AU - Owen, C

AU - Verdugo, M

AU - Wu, J

AU - Punnoose, EA

AU - Jiang, YW

AU - Wang, Johnny

AU - Boyer, M

AU - Humphrey, K

AU - Mobasher, M

AU - Kipps, TJ

PY - 2019

Y1 - 2019

U2 - 10.1200/jco.18.01580

DO - 10.1200/jco.18.01580

M3 - Article

SN - 0732-183X

VL - 37

SP - 269-+

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 4

ER -